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Introduction
A Disease Severity Scoring System (DS3) measures disease
burden in patients. It consists of critical health domains,
each described by relevant clinical assessment(s) quanti-
fied via reliable, valid and feasible methods. DS3s are par-
ticularly useful in rare, heterogeneous diseases in which
evaluating severity and prognosis is difficult. Properly
configured, a DS3 provides inter- and intra-patient com-
parisons through time across critical organ systems. A DS3
is being developed for Pompe disease, a rare, autosomal
recessive, and heterogenous, neuromuscular disorder.
Description
Experts were assembled to identify critical Pompe disease
health domains. A broader "Delphi" physician group
helped capture standard medical practice(s) for severity
measurement within each critical domain: Cardiac, Respi-
ratory, Proximal Muscle, Physician Reported Outcomes
and Patient Reported
Outcomes
Within each domain, 1–2 clinical assessments were iden-
tified. To test this preliminary model, 9 cases from the
Pompe Registry representing a severity spectrum were
scored.
Results
Results were compared to results from a blinded small
expert group assessment of the cases using a scale similar
to the Clinical Global Impression (CGI) Severity scale,
yielding a 0.93 coefficient of correlation, indicating pre-
liminary DS3 consistency with expert opinion, suggesting
preliminary DS3 validity, reliability and relevance. Valid-
ity and reliability testing are being completed with stand-
ardized methods.
Conclusion
Preliminary results indicate the Pompe DS3 model will
help standardize disease terminology and highlight key
clinical assessments to quantify disease severity. This tool
can become a universal disease "staging" system that per-
mits more exact prediction of important disease outcomes
and identify the need for specific medical interventions.
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